Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Yunqi Capital, a 5.1% STAAR Surgical (NASDAQ:STAA) shareholder, praised STAAR’s Q3 2025 results and urged STAAR’s board to terminate the proposed sale to Alcon (SIX/NYSE:ALC). Yunqi highlighted cost discipline: reported operating expenses of $59.4M, excluding $5.9M merger costs an implied run rate of $214M vs prior guidance of $225M. Cash, cash equivalents and investments rose to $192.7M from $189.9M sequentially. Yunqi says China ICL demand recovered, disputes Alcon’s selective use of IQVIA and McKinsey data, and calls Alcon’s $28/share proposal opportunistic. Yunqi notes ~72% of outstanding STAAR shares reportedly voted against the deal as of Oct 23, 2025, and offers to join the board to add shareholder perspective.
Broadwood Partners (investor in STAAR Surgical, NASDAQ:STAA) on Nov 4, 2025 urged shareholders to vote AGAINST Alcon’s (NYSE:ALC) proposed acquisition of STAAR. Broadwood says it owns 27.5% of STAAR and criticizes an Alcon presentation as "fallacious" and misleading, arguing the STAAR board should not delay the shareholder vote or seek Alcon’s permission to run a strategic process. Broadwood cites what it describes as broad shareholder and proxy-advisor opposition to the deal and highlights prior procedural adjournments of STAAR’s Special Meeting. The statement frames the transaction as distracting and harmful to STAAR’s business and directs shareholders to a campaign site for more information.
Summary not available.
Company (NYSE:ALC) faced public shareholder resistance after Yunqi Capital, a 5.1% shareholder, sent a letter urging STAAR Surgical’s board to terminate the proposed merger announced Aug 5, 2025.
Yunqi cited a postponed special meeting now set for December 3, 2025, reported vote results showing roughly 72% of outstanding shares opposed the merger and about 81% opposed a $55 million executive compensation package, and said Alcon provided no commitment to increase consideration as of October 24, 2025.
STAAR Surgical (merger with Alcon, ALC) postponed its Special Meeting of Stockholders from November 6, 2025 to December 3, 2025 at 8:30 a.m. PT because of ongoing discussions with Alcon. The new record date for voting eligibility is the close of business on October 24, 2025. Stockholders holding shares as of that record date will be eligible to vote at the postponed meeting, and STAAR will provide a notice and meeting materials in advance. Stockholders with voting questions are instructed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at the provided toll-free and broker phone numbers.
Summary not available.
Summary not available.
Alcon (SIX/NYSE: ALC) and STAAR Surgical (NASDAQ: STAA) agreed to adjourn STAAR’s Special Meeting of Stockholders originally scheduled for October 23, 2025 in connection with STAAR’s merger agreement with Alcon. The Special Meeting is adjourned until 8:30 a.m. Pacific Time on November 6, 2025. No other business will be conducted at the Special Meeting. The record date for stockholders eligible to vote remains the close of business on September 12, 2025. Stockholders with voting questions are directed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at toll-free +1 877-750-8233 or banks/brokers +1 212-750-5833.
Yunqi Capital (NASDAQ:STAA), a 5.1% STAAR shareholder, urged the board to hold the special shareholder meeting on October 23, 2025 and reiterated its opposition to the proposed sale to Alcon. Yunqi criticized STAAR’s pre-merger process and called recent company disclosures “disingenuous.”
Yunqi highlighted preliminary Q3 results: China revenue YTD $142.6M, estimated Q3 China revenue ≈$54.4M, $25.6M consignment revenue, and said Q3 sales exceeded consensus by 2.8%. Yunqi projects China sales of $180–200M for 2026 versus STAAR’s $160M guide and flagged missing margin/profit detail before the vote.
Summary not available.